|
Market Closed -
Nasdaq
04:00:00 21/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 540.26 USD | -2.14% |
|
+4.61% | +19.17% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 563.12 | +4.23% | 25 | ||||||
| 1,310.9 | +5.34% | 28 | ||||||
| 272.5 | +1.92% | 22 | ||||||
| 276.59 | +5.64% | 29 | ||||||
| 370.31 | -0.4% | 18 | ||||||
| 154.23 | -2.48% | 21 | ||||||
| 212.3 | +28.74% | 22 | ||||||
| 388.48 | -10.43% | 29 | ||||||
| 313.7 | +5.93% | 24 | ||||||
| 157.41 | +9.74% | 27 | ||||||
| 28.61 | +2.94% | 26 | ||||||
| 66.21 | +1.13% | 24 | ||||||
| 94.28 | +21.2% | 23 | ||||||
| 21.61 | +12.54% | 20 | ||||||
| 9,350 | +31.67% | 15 | ||||||
| 6,450.19 | +10.73% | 16 | ||||||
| 56.83 | +16.92% | 18 | ||||||
| 75.9 | +53.33% | 16 | ||||||
| 41.4 | +12.47% | 10 | ||||||
| 4.208 | +16.93% | 17 | ||||||
| Average | 1,010.44 | +11.40% | 22 | ||||||
| Weighted average by Cap. | 710.23 | +6.20% | 24 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
